Skip to main content

Table 1 Distribution of TILs according to patient and tumour characteristics (n = 477)

From: Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up

Variable TIL low (< 10%)
n (%)
TIL intermediate (10–49%)
n (%)
TIL high (≥ 50%)
n (%)
P valuea
Age (years) 0.02
 < 40 41 (44) 32 (34) 21 (22)  
 ≥ 40 207 (54) 125 (33) 51 (13)  
Nodal status 0.34
 0 65 (47) 42 (31) 30 (22)  
 1–3 137 (59) 66 (28) 30 (13)  
 ≥ 4 46 (44) 47 (45) 12 (11)  
 Missing 0 2 0  
Tumour size (mm) 0.06
 ≤ 20 97 (57) 52 (31) 20 (12)  
 > 20 151 (49) 104 (34) 52 (17)  
 Missing 0 1 0  
Histological grade (NHG) < 0.001
 1 44 (86) 7 (14) 0  
 2 135 (70) 52 (27) 5 (3)  
 3 56 (27) 91 (43) 64 (30)  
 Missing 13 7 3  
ER < 0.001
 Negative 45 (29) 63 (40) 48 (31)  
 Positive 203 (63) 94 (29) 24 (8)  
PR < 0.001
 Negative 41 (27) 63 (41) 50 (33)  
 Positive 206 (64) 93 (29) 21 (7)  
 Missing 1 1 1  
HER2 0.001
 Negative 205 (56) 109 (30) 50 (14)  
 Positive 22 (33) 28 (42) 16 (24)  
 Missing 21 20 6  
LVI 0.87
 Absent 140 (54) 76 (30) 42 (16)  
 Present 108 (50) 81 (37) 28 (13)  
 Missing 0 0 2  
Ki67 (%) < 0.001
 ≤ 10 126 (71) 40 (23) 12 (7)  
 11–25 60 (56) 33 (31) 14 (13)  
 ≥ 26 22 (20) 53 (48) 36 (32)  
 Missing 40 31 10  
Histopathological type < 0.001
 Ductal/NST 200 (52) 134 (35) 48 (13)  
 Lobular 29 (81) 7 (19) 0  
 Medullary 0 3 (13) 20 (87)  
 Other 9 (75) 2 (17) 1 (8)  
 Missing 10 11 3  
Subtype < 0.001
 ER+/HER2− 176 (69) 65 (25) 16 (6)  
 HER2+ 22 (33) 28 (42) 16 (24)  
 TNBC 20 (21) 42 (44) 33 (35)  
 Missing 30 22 7  
Total 248 (52) 157 (33) 72 (15)  
  1. a Chi2 test for trend, except for the non-ordinal variables histopathological type and subtype, when conventional chi2 test was used
  2. Abbreviations: ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, LVI lymphovascular invasion, NST no special type, NHG Nottingham histological grade, PR progesterone receptor, TILs tumour-infiltrating lymphocytes, TNBC triple-negative breast cancer